Skip to main content

Table 1 Clinical characteristics of patients with BSI within 2-weeks before death

From: The epidemiology of bloodstream infection contributing to mortality: the difference between community-acquired, healthcare-associated, and hospital-acquired infections

Ā 

Overall (280)

Community-acquired (71)

Healthcare-associated (53)

Hospital-acquired (156)

P value

Post-hoc analysis

Age

69.92ā€‰Ā±ā€‰12.95

72.99ā€‰Ā±ā€‰13.57

68.75ā€‰Ā±ā€‰12.37

68.92ā€‰Ā±ā€‰12.72

0.069

Ā 

Sex (male)

168 (60.0)

48 (67.6)

34 (64.2)

86 (55.1)

0.162

Ā 

Malignancy

118 (42.1)

19 (26.8)

34 (64.2)

65 (41.7)

ā€‰<ā€‰0.001

HCA>CA,HA

Diabetes

85 (30.4)

24 (33.8)

13 (24.5)

48 (30.8)

0.532

Ā 

Hypertension

120 (42.9)

30 (42.3)

27 (50.9)

63 (40.4)

0.411

Ā 

Cardiovascular disease

73 (26.1)

13 (18.3)

8 (15.1)

52 (33.3)

0.007

HA>HCA

Pulmonary disease

26 (9.3)

7 (9.9)

1 (1.9)

18 (11.5)

0.093

Ā 

Liver disease

56 (20.0)

24 (33.8)

10 (18.9)

22 (14.2)

0.004

CA>HA

Rheumatologic disease

12 (4.3)

1 (1.4)

1 (1.9)

12 (4.3)

0.184

Ā 

Renal disease

25 (8.9)

3 (4.2)

3 (5.7)

19 (12.2)

0.136

Ā 

Solid organ transplantation

4 (1.4)

0 (0.0)

0 (0.0)

4 (2.6)

0.392

Ā 

Prior major surgery

35 (12.5)

0 (0.0)

4 (7.5)

31 (19.9)

ā€‰<ā€‰0.001

HA>CA

Prior antibiotics use

124 (44.3)

2 (2.8)

34 (64.2)

88 (56.4)

ā€‰<ā€‰0.001

HCA,HA>CA

  1. Data represent the number (%) of patients, unless otherwise specified
  2. BSI bloodstream infection; HCA healthcare-associated infection; CA community-acquired infection; HA hospital-acquired infection